Arqit Quantum (NASDAQ:ARQQ) Azioni

Arqit Quantum

Arqit Quantum Inc is a cybersecurity company that has pioneered a symmetric key agreement technology that makes the communications links of any networked device or data at rest secure against current and future forms of cyber attack - even an attack from a quantum computer. The company delivers its symmetric key agreement technology via its product SKA-Platform. The firm operates in one segment that is, the provision of cybersecurity services. The company operates and generates its revenue from UK.

Genetic,Research,And,Biotech,Science,Concept.,Human,Biology,And,Pharmaceutical

News

Pre-Market Outlook

Markets

Trading Ideas

ARQQ

SIMO

Due azioni tech mostrano segnali preoccupanti di ipercomprato. Una guida sui titoli da monitorare a giugno per evitare brutte sorprese.

2 azioni che potrebbero affondare il tuo portafoglio a giugno

Arqit Quantum Inc

WIIM

BURU

NUBURU shares are trading higher after the company said the regulatory approval process for its acquisition of Tekne SpA is progressing 'positively and in line with expectations.'

LAES

WKEY

WISeKey's Subsidiary WISeSat.Space Is On Target To Deploy 100-Satellite Constellation By 2027 In Cooperation With WISekey And SEALSQ

Government

Regulations

NUBURU Says Regulatory Approval Process For Acquisition Of Tekne SpA Is 'progressing positively and in line with expectations'

Cantor Fitzgerald analyst Eric Schmidt reiterates Avidity Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) with a Overweight and maintains $96 price target.

Price Target

Reiteration

Analyst Ratings

Cantor Fitzgerald Reiterates Overweight on Avidity Biosciences, Maintains $96 Price Target

Stock Split

HSDT

Helius Medical Technologies Announces 1-For-50 Reverse Split Of Its Class A Common Stock

Offerings

OTRK

Ontrak Health Prices Public Offering Of 6,666,667 Shares And 26,666,668 Warrants At Combined Public Offering Price Of $0.60 Per Share And Accompanying Warrant; Gross Proceeds ~$4M

Omeros Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) today announced the recent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).
The MAA includes response-based analyses in narsoplimab-treated TA-TMA patients as well as analyses comparing overall survival between narsoplimab-treated patients and a well-matched external control group. Collectively, the results demonstrate a 61% response rate and, compared to the matched external control, a three-fold improvement in overall survival. The submission also includes outcomes in over 130 TA-TMA patients treated with narsoplimab under Omeros' expanded access program.
Narsoplimab has been granted orphan drug designation by the EMA for treatment in hematopoietic stem cell transplant, enabling review of the MAA through the centralized procedure. This allows for a single marketing authorization to cover all EU member states and the European Economic Area countries of Iceland, Liechtenstein and Norway.
The review procedure begins in mid-July and will follow a standard review timeline. The Committee for Medicinal Products for Human Use (CHMP) will conduct the scientific assessment and will issue an opinion at the end of the review. This opinion is typically adopted by the European Commission, with a final decision expected in mid-2026.
The MAA submission follows the acceptance for review by the U.S. Food and Drug Administration (FDA) of the resubmission of the Biologics License Application (BLA) for narsoplimab for the treatment of TA-TMA. The resubmission was assigned a Prescription Drug User Fee Act (PDUFA) target action date of September 25, 2025.

OMER

Omeros Submits MAA To EMA For Narsoplimab For Treatment Of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy

JMP Securities analyst Jonathan Wolleben reiterates ProQR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) with a Market Outperform and maintains $8 price target.

PRQR

JMP Securities Reiterates Market Outperform on ProQR Therapeutics, Maintains $8 Price Target

CISO

CISO Global Files Renewal Of S-3 Shelf Registration, Reducing Total Shelf From $300M To $100M

Macro Economic Events

Econ #s

Economics

US PCE Price index (YoY) (May) +2.3% vs +2.3% Est.

USA Core PCE Price Index (MoM) (May) +0.2% vs +0.1% Est.

PCE Price Index MoM For For May 0.1% Vs 0.1% Expected

Macro Notification

General

Core PCE Price Index (YoY) (May) +2.7% vs +2.6% Est.

JMP Securities analyst Patrick Walravens reiterates Sprinklr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CXM#NYSE">CXM</a>) with a Market Outperform and maintains $17 price target.

JMP Securities Reiterates Market Outperform on Sprinklr, Maintains $17 Price Target

JMP Securities analyst Silvan Tuerkcan reiterates CRISPR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>) with a Market Outperform and maintains $86 price target.

CRSP

JMP Securities Reiterates Market Outperform on CRISPR Therapeutics, Maintains $86 Price Target

Jefferies analyst Peter Abramowitz initiates coverage on Armada Hoffler Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AHH#NYSE">AHH</a>) with a Buy rating and announces Price Target of $8.

Initiation

Jefferies Initiates Coverage On Armada Hoffler Properties with Buy Rating, Announces Price Target of $8

Alibaba Group Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) showcased an <a target="_blank" href="https://www.benzinga.com/topic/artificial-intelligence" rel="noreferrer noopener">artificial intelligence (AI) model</a> designed to identify gastric cancer, co-developed by Alibaba&#8217;s Damo Academy and the Zhejiang Cancer Hospital.
The model can detect gastric cancer, even in early stages, by scanning computed tomography (CT) images. The AI model known as Grape derived its name from the &#8220;gastric cancer risk assessment procedure.&#8221;
Grape can analyze three-dimensional CT scans to detect and segment gastric cancer, also known as stomach cancer, SCMP <a target="_blank" href="https://www.scmp.com/tech/article/3315931/alibaba-touts-worlds-first-ai-model-detect-stomach-cancer-even-early-stages" rel="noreferrer noopener">reported</a> on Thursday.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/tech/25/06/46069690/alibaba-accelerates-global-ai-push-targets-overseas-data-centers" rel="noreferrer noopener">Alibaba Accelerates Global AI Push, Targets Overseas Data Centers</a>
Diagnosis of gastric cancer currently requires an endoscopy, prompting the insertion of a camera and tiny biopsy instruments through the throat.
Citing a paper published in Nature Medicine on Tuesday, SCMP reported that the Grape model significantly outperformed radiologists.
This initiative underscores Alibaba&#8217;s strategic move to unlock value by integrating AI technology into its various operations, including healthcare.
Following a similar approach, Alibaba had already made a breakthrough in detecting pancreatic cancer in 2023, showcasing a growing focus on applying its AI expertise to critical medical challenges.
Beyond healthcare, Alibaba is also making waves in the general AI landscape. Last week, Alibaba revealed new Qwen3 AI models, <a target="_blank" href="https://www.benzinga.com/markets/tech/25/06/45975004/alibaba-updates-llms-to-power-ai-on-apple-devices-in-china" rel="noreferrer noopener">signaling a possible</a> collaboration or rollout with Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) in China amid rising local AI demand.
Alibaba co-founder and Chair&nbsp;Joe Tsai opted to <a target="_blank" href="https://www.benzinga.com/markets/tech/25/06/45925331/alibaba-co-founder-sees-open-source-qwen-driving-cloud-demand" rel="noreferrer noopener">open-source its</a> Qwen models, citing their potential to drive demand for&nbsp;AI&nbsp;applications and cloud computing.
Open source gives the public access to a software program&#8217;s source code, allowing third-party developers to modify or scale up its capabilities.
IMARC Group&nbsp;expects&nbsp;the global <a target="_blank" href="https://www.benzinga.com/markets/tech/25/06/45816525/alibaba-releases-new-open-source-ai-models-with-multilingual-and-code-support" rel="noreferrer noopener">open-source intelligence</a> market to reach&nbsp;$58.0 billion&nbsp;by 2033, at a&nbsp;CAGR of 15.93%&nbsp;from 2025 to 2033.
Price Action:&nbsp;BABA stock traded higher by 0.11% to $114.06 premarket at&nbsp;the last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46117348/meta-secures-more-clean-energy-for-power-hungry-ai-and-data-center-growth" target="_blank" rel="noreferrer noopener">Meta Secures More Clean Energy For Power Hungry AI And Data Center Growth</a></li>
</ul>
Photo by Aunt Spray via Shutterstock

Asia

Health Care

Tech

Media

AAPL

BABA

Alibaba's AI Model Outperforms Radiologists In Early Gastric Cancer Detection

TD Securities analyst John Mould initiates coverage on Fortis (TSX:<a class="ticker" href="https://www.benzinga.com/stock/FTS#TSX">FTS</a>) with a Buy rating and announces Price Target of C$74.

TSX:FTS

TD Securities Initiates Coverage On Fortis with Buy Rating, Announces Price Target of C$74

Editor&#8217;s Note: The article has been updated to include comments from the office of Prime Minister Benjamin Netanyahu.
U.S. President&nbsp;Donald Trump and Israeli Prime Minister&nbsp;Benjamin Netanyahu&nbsp;are reportedly working on a plan to end the ongoing war in Gaza and expand the Abraham Accords, with new countries joining the peace agreement.
What Happened: The plan, as reported by&nbsp;Israel Hayom, would require Israel&nbsp;to commit to supporting a&nbsp;future Palestinian state. This proposal was discussed during a phone call between Trump and Israeli Prime Minister&nbsp;Benjamin Netanyahu&nbsp;on Monday, <a href="https://www.timesofisrael.com/netanyahu-trump-said-working-on-plan-to-end-gaza-war-and-expand-abraham-accords/">stated </a>The Times Of Israel. 
The leaders have reportedly agreed to bring the Gaza war to an end within a two-week timeline, which would require Israel to cease its military operations&nbsp;and Hamas to release the&nbsp;remaining 50 hostages. Following this, the leadership of the Palestinian group would be exiled, and the governance of the war-ravaged region would be jointly undertaken by four Arab nations, including the UAE and Egypt.
The plan also includes provisions for the rehabilitation of the Gaza Strip, absorption of Gazans wishing to emigrate by several undisclosed countries and Israel&#8217;s&nbsp;backing for a future two-state&nbsp;solution contingent on reforms&nbsp;by the Palestinian Authority. In&nbsp;exchange, Washington would acknowledge Israeli sovereignty over certain areas of the West Bank.
Once the war ends and Israel reaffirms its commitment to a two-state solution, Saudi Arabia and Syria are expected to establish diplomatic ties with Israel under the Abraham Accords, with other Arab and Muslim countries likely to follow.
Meanwhile, Netanyahu&#8217;s office <a href="https://www.columbusjewishnews.com/jns/pmo-denies-israel-us-talks-on-two-state-solution-took-place/article_45953d88-523b-547b-a1b0-4f46044e5a95.html">said</a>, &#8220;The conversation&#8230;did not take place." 
 "Israel was not presented with the political proposal supposedly described in the article, and it obviously did not agree to it."
SEE ALSO:&nbsp;<a href="https://benzinga.com/news/health-care/25/06/46131597/bill-gates-says-he-knows-for-a-fact-that-more-children-will-die-due-to-us-health-aid-cuts-and-he" target="_blank" rel="noreferrer noopener">Bill Gates Says He Knows For A &#8216;Fact&#8217; That More Children Will Die Due To US Health Aid Cuts And He&#8217;s Taking The &#8216;Proof&#8217; To Congress</a>
Why It Matters: This development comes amid other significant events in the region. Trump recently&nbsp;urged Israel to cancel or pardon <a href="https://www.benzinga.com/news/politics/25/06/46108200/trump-calls-for-canceling-netanyahus-witch-hunt-corruption-trial-calls-it-a-travesty-of-justice">Netanyahu&#8217;s corruption</a> trial, calling it a &#8220;witch hunt.&#8221; This public support from Trump could have implications for the Israeli political landscape.
Meanwhile, U.S. Senator&nbsp;Elizabeth Warren&nbsp;recently&nbsp;<a href="https://www.benzinga.com/news/politics/25/06/46068097/elizabeth-warren-presses-marco-rubio-over-potential-500-million-usaid-diversion-to-controversial-gaza-foundation-report">raised concerns</a> about a proposal&nbsp;to redirect $500 million from USAID to the Gaza Humanitarian Foundation, a controversial organization. This proposal, if implemented, could have a significant impact on the humanitarian situation in Gaza.
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://www.benzinga.com/news/politics/25/06/46132996/marco-rubio-says-everything-under-the-mountains-is-in-bad-shape-rubbishes-claim-trump-strikes-only-bought-iran-time">Marco Rubio Says &#8216;Everything Under The Mountains Is In Bad&#8217; Shape, Rubbishes Claim Trump Strikes Only Bought Iran Time</a> </li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Trump And Israel's Netanyahu Working On Plan To End Gaza War, Expand Abraham Accords: Report (UPDATED)

ACHV

Achieve Life Sciences shares are trading lower after the company announced a $45 million public offering.

Contracts

Press Releases

Global tier 1 telco operator signs three year agreement with Arqit to secure its Quantum-Safe Network-as-a-Service (NaaS) Deployment

RSG purchases test and integration license from Arqit to deliver quantum-secure networks and prepare for commercial-scale deployment

Management

Arqit appoints new Chief Technology Officer to drive innovation and growth

Arqit delivers quantum-safe protection enhanced by confidential computing

Arqit, in collaboration with Equus and Intel, demonstrates a world-first Quantum-Safe CSfC-Compliant MACP Architecture for Classified Mobile Communications

Small Cap

Opinion

Quantum's Rise Could Mirror the AI Boom--Only Faster

Earnings

Arqit Quantum Inc. Sets First Half 2025 Conference Call for Thursday, May 22, 2025 at 11:00 a.m. ET

Arqit Quantum Inc. Announces Financial Results for First Half of Fiscal Year 2025

Arqit acquires Ampliphae's technology IP, enhancing its global encryption portfolio

Arqit Joins Oracle Defense Ecosystem

ARQQW

CSE:SCPE

INTC

QBTS

SCPCF

Agora

Digital Turbine

Blend Labs

Bit Digital

Consensus Cloud Solutions, Inc. - Common Stock

Consensus Cloud Solns

Cerence

Diginex

Daily Journal Corp. (S.C.) - Common Stock

Daily Journal

Domo

E2open Parent Holdings, Inc.Class A Common Stock

E2open Parent Holdings

Exodus Movement, Inc. Class A Common Stock

Exodus Movement

BitFuFu

Gorilla Technology Group Inc. - Ordinary shares

Gorilla Tech Gr

AMTD Digital Inc. American Depositary Shares (every five of which represent two Class A Ordinary Shares)

Comments

Arqit Quantum

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO